Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, ...

US pharma major Eli Lilly today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase III clinical trials ...

IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

An experimental once-weekly insulin known as efsitora has shown comparable effectiveness to daily insulin regimens in managing blood sugar levels among adults with type 2 diabetes, according to ...

Once-weekly efsitora vs once-daily degludec was associated with comparable glycemic control outcomes and improved ...

Biocon Biologics Ltd. (BBL) on Monday announced that its Malaysian subsidiary, Biocon Sdn. Bhd., has surpassed the supply of ...

A new study from Weill Cornell Medicine-Qatar (WCM-Q), a member of Qatar Foundation, is drawing global attention for its investigation into how insulin resistance (InsR) may ...

GRAFTON, W.Va. — A Preston County woman charged with killing her mother with insulin at her Grafton home in 2023 has pleaded guilty to a charge of voluntary manslaughter. Kelly Moore (WVRJA ...

FRIDAY, June 27, 2025 (HealthDay News) -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among ...

News Health Diabetes Experts say two superfoods slash blood sugar levels before needing insulin There are ways you can lower blood sugar levels naturally, including eating superfoods rich in ...